Strong Sales of Cresemba® Lead to Milestone Payment
Basilea Pharmaceutica Ltd, a biopharmaceutical company focused on addressing the needs of patients with serious bacterial and fungal infections, has announced that the impressive sales performance of the antifungal Cresemba® (isavuconazole) by its licensing partner, Pfizer Inc., in the Asia Pacific region and China has surpassed the sales threshold. This achievement has triggered a milestone payment of USD 1.25 million.
CEO David Veitch's Remarks
David Veitch, the Chief Executive Officer of Basilea, commented: “Reaching the threshold for the third milestone payment for Asia Pacific and China this year highlights the robust sales performance and growth of Cresemba in this area. We are delighted that Cresemba continues to fulfill the medical needs of patients battling life-threatening invasive mold infections.”
About Cresemba®
The licensing agreement between Basilea and Pfizer for Cresemba encompasses Europe (excluding the Nordic countries) and 16 countries across the Asia Pacific region and China.
Cresemba is approved and marketed in over 70 countries, which includes the United States, most EU member states, and various countries both inside and outside Europe. Recent market data indicates that total global sales of Cresemba reached USD 489 million in the 12 months from April 2023 to March 2024, marking a 24 percent increase compared to the previous year.
About isavuconazole (Cresemba®)
Isavuconazole is an intravenous (i.v.) and oral azole antifungal, marketed under the name Cresemba®. Basilea has established multiple licensing and distribution agreements for isavuconazole, covering approximately 115 countries. In the European Union, as well as in Iceland, Liechtenstein, Norway, and the U.K., isavuconazole is approved for treating adult patients with invasive aspergillosis and for those with mucormycosis when amphotericin B is not suitable. In China, both oral and intravenous formulations are approved for adult patients with invasive aspergillosis and invasive mucormycosis. Isavuconazole also holds approvals in the United States and several other countries in Europe and beyond, including Japan, and it has orphan drug designation in the US, Europe, and Australia for its approved uses.
About Basilea
Basilea is a commercial-stage biopharmaceutical company that was founded in 2000 and is based in Switzerland. The company is dedicated to discovering, developing, and commercializing innovative medications to address the needs of patients suffering from severe bacterial or fungal infections. Basilea has successfully launched two hospital brands: Cresemba for treating invasive fungal infections and Zevtera for bacterial infections. Additionally, the company has a portfolio of preclinical and clinical anti-infective assets. Basilea is listed on the SIX Swiss Exchange.
Contact Information
If you need further information, please reach out to:
Peer Nils Schröder, PhD
Head of Corporate Communications & Investor Relations
Basilea Pharmaceutica International Ltd
Hegenheimermattweg 167b
4123 Allschwil
Switzerland
Phone: +41 61 606 1102
Email: media_relations@basilea.com | investor_relations@basilea.com
Frequently Asked Questions
What milestone payment has Basilea received?
Basilea has received a milestone payment of USD 1.25 million due to strong sales performance of Cresemba in the Asia Pacific region and China.
Who is Basilea's license partner for Cresemba?
Pfizer Inc. is the license partner for Cresemba.
In how many countries is Cresemba approved?
Cresemba is approved and marketed in more than 70 countries worldwide.
What therapeutic indications does isavuconazole target?
Isavuconazole targets invasive aspergillosis and invasive mucormycosis in adults.
How does Basilea contribute to patient care?
Basilea develops and commercializes innovative drugs to meet critical medical needs for patients with severe infections.
